# Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding

> **NCT00152399** · PHASE2 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 370 (—)

## Conditions studied

- Peptic Ulcer

## Interventions

- **DRUG:** Somatostatin UCB (drug)

## Key facts

- **NCT ID:** NCT00152399
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 370 (—)
- **Last updated:** 2012-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152399, "Study to Assess the Efficacy and Safety of Somatostatin in the Treatment of Acute Severe Upper Gastrointestinal Bleeding". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00152399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*